Corcept Therapeutics Incorporated (CORT)
| Market Cap | 2.67B |
| Revenue (ttm) | 353.87M |
| Net Income (ttm) | 106.01M |
| Shares Out | 115.41M |
| EPS (ttm) | 0.85 |
| PE Ratio | 26.81 |
| Forward PE | 22.78 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $22.79 |
| Previous Close | $22.77 |
| Change ($) | 0.03 |
| Change (%) | 0.11% |
| Day's Open | 22.68 |
| Day's Range | 22.30 - 22.83 |
| Day's Volume | 259,437 |
| 52-Week Range | 11.91 - 31.18 |
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
With solid revenue growth, these stocks have the potential to more than triple over the next few years.
Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.
MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...
Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.
MENLO PARK, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...
AMRX vs. CORT: Which Stock Is the Better Value Option?
Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021.
Financial Highlights, 2021 Revenue Guidance and Legal Update
Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results ...
Time will always be on the investor's side.
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
On Friday, Corcept Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Corcept Therapeutics Sees Its Composite Rating Rise To 96 appeared first on Investor's Bus...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...
Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB. The post Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24...
MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...
Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year.
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript
Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 22.58% over the past year to $0.24, which...
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on No...
A patent decision on its cortisol therapy Korlym is expected to be rendered next month.
Growth-focused investors may be interested in the following stocks since their price-earnings ratios still trade below 20 and their trailing 12-month earnings per share have grown significantly over the...
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well.
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe me...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.
The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript
MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on...
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...
MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared first on Inve...
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...
MENLO PARK, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Is (CORT) Outperforming Other Medical Stocks This Year?
MENLO PARK, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...
This biotech company has seen huge growth over the past five years.
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cu... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Joseph Belanoff | Employees 236 |
| Stock Exchange NASDAQ | Ticker Symbol CORT |
Financial Performance
In 2020, CORT's revenue was $353.87 million, an increase of 15.46% compared to the previous year's $306.49 million. Earnings were $106.01 million, an increase of 12.56%.
Analyst Forecasts
According to 4 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 27.00, which is an increase of 18.47% from the latest price.